Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immunoprecise Antibodies Ltd
(NQ:
IPA
)
1.290
+0.030 (+2.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunoprecise Antibodies Ltd
< Previous
1
2
3
4
Next >
Small Cap Biotechnology Companies Release Positive Quarterly Results (IPA, AVIR, LQDA, ABSI, APVO)
May 31, 2022
Via
AB Newswire
Biotech Recovery Accelerates These Companies Benefit (IPA, SIGA, MNKD, INO, CTIC)
May 25, 2022
Via
AB Newswire
IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant
May 09, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
April 20, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings
April 14, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial Intelligence
March 29, 2022
From
ImmunoPrecise Antibodies
Via
Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2022
March 16, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Selected to Work with Elektrofi on COVID-19 Therapeutic Delivery and Future Pandemic Preparation under SBIR Contract from Defense Health Agency within US Department of Defense
March 14, 2022
From
Elektrofi and ImmunoPrecise Antibodies
Via
Business Wire
Immunotherapeutic PolyTope® from ImmunoPrecise (IPA) Potently Neutralizes the SARS-CoV-2 Omicron Variant – Moves Towards FDA/IND-Submission
January 31, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Relocates European Subsidiary to LEED Certified Campus to Continue to Advance its Antibody Research Operations and Environmental Sustainability
January 18, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Announces Grant of Stock Options
January 17, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Announces Grant of Stock Options
January 11, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Announces Grant of Stock Options
January 03, 2022
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies and ChemPartner Biologics Announce PolyTope® TATX-03 Antibody Cocktail Manufacturing Collaboration
December 20, 2021
From
IMMUNOPRECISE ANTIBODIES LTD.
Via
Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
December 13, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2022
December 07, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Update on its SARS-CoV-2 PolyTope™ Multi-Antibody Cocktail Development Program
November 30, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise to Present at the Benchmark Company’s Discovery One-on-One Virtual Video Investor Conference on Thursday December 2, 2021
November 24, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Announces Resignation of Director
November 09, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Announces At-The-Market Facility of up to US$50 Million
October 13, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre
October 07, 2021
From
ImmunoPrecise Antibodies Ltd
Via
Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
September 09, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise’s Dutch Subsidiary Receives French Research Tax Credit (CIR) Accreditation
September 08, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)
September 07, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Announces Participation at the H.C. Wainwright 23nd Annual Global Investment Conference on September 13-15, 2021 (Virtual Conference)
September 07, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2022
September 03, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Welcomes Vice President of Client Relations and Vice President of Marketing to its Leadership Team, Accelerating Its Growth and Expansion Plans
August 04, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2021
July 28, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays
July 22, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise to Report Financial Results and Business Highlights for Fiscal Year 2021
July 15, 2021
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.